Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
LUMO
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q4.22
N/A
-0.98
vs -0.68
Q1.23
N/A
-0.89
vs -0.92
Q2.23
N/A
-1.09
vs -0.94
Q3.23
N/A
-1.04
vs -0.86
Q4.23
N/A
-1.17
vs -0.98
Q1.24
N/A
-1.29
vs -0.89
Q2.24
N/A
-0.93
vs -1.09
Q3.24
N/A
-0.90
vs -1.04
Q4.24
N/A
-0.67
vs -1.17
Q1.25
N/A
-0.38
vs -1.29
Sales Growth
YoY
Current
Estimates
Q4.22
+133%
512K vs 220K
Q1.23
+523%
691K vs 111K
Q2.23
+31%
527K vs 403K
Q3.23
-99%
7K vs 497K
Q4.23
+61%
826K vs 512K
Q1.24
-76%
165K vs 691K
Q2.24
-7%
488K vs 527K
Q3.24
+10271%
726K vs 7K
Q4.24
-46%
443.3K vs 826K
Q1.25
-9%
150K vs 165K
Return on Equity
QoQ
Q4.22
-13%
-0.13
vs -0.11
Q1.23
-13%
-0.13
vs -0.13
Q2.23
-20%
-0.20
vs -0.13
Q3.23
-23%
-0.23
vs -0.20
Q4.23
-35%
-0.35
vs -0.23
Q1.24
-60%
-0.60
vs -0.35
Q2.24
-73%
-0.73
vs -0.60
Q3.24
-152%
-1.52
vs -0.73
Institutionnal Ownership
QoQ
Q1.23
34
34
vs 37
-8%
Q2.23
34
34
vs 34
NA
Q3.23
33
33
vs 34
-3%
Q4.23
37
37
vs 33
12%
Q1.24
35
35
vs 37
-5%
Q2.24
35
35
vs 35
NA
Q3.24
28
28
vs 35
-20%
Q4.24
1
1
vs 28
-96%
globenewswire.com
14 hours ago
prnewswire.com
15 hours ago
prnewswire.com
15 hours ago
Forecast
93%2025-Revenue
-112%2025-EPS
82%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
H.C. Wainwright
downgradePrevious: Not converted
2024-10-24
Now: Neutral
EF Hutton
initialisePrevious: Not converted
2024-09-24
Now: Buy
Jefferies
downgradePrevious: Not converted
2022-11-14
Now: Hold
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
Relative Strenght
84
Volume Buzz
280%
Earning Acce
Yes
Dist 52w H.
5%Quote Panel
Key Metrics
Relative Strength
LUMO
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
